CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
Bortezomib-based triple-drug combination has greatly improved the response rate of multiple
myeloma patients. Bortezomib,doxorubicin,and dexamethasone (PAD) is commonly used in clinical
practice.Recent studies have found that cyclophosphamide, bortezomib,and dexamethasone
(CyBorD)seems better than PAD in efficacy. However, there is no randomized phase 3 trial
comparing these two regimens in the treatment of newly diagnosed multiple myeloma patients.In
this study, the investigators will compare the efficacy and safety of these two regimens
using once-weekly subcutaneous injection of bortezomib.